Catalent

There continues to be a rapid expansion in the orally inhaled therapeutic pipeline, underpinned by scientific, technological, manufacturing and regulatory advances across drug products and devices. In this Q&A article, Catalent experts Carolyn Berg and Carla Vozone discuss innovations in orally inhaled drug products, in particular dry powders for inhalation.

Thursday, February 24, 2022 at 11am EST| 8am PST| 4pm GMT|5pm CET This webinar will discuss the challenges, opportunities, and advantages of intranasal drug delivery and why it has drawn increasing interest as a route of administration. *** On demand available after final airing until November 18, 2022.***

One of the challenges facing gene therapy manufacturing is the lack of standardization in the process. Standardized methods, materials, analytics, and documentation can help reduce supply chain bottlenecks, increase efficiencies and lead to accelerated development timelines and smoother regulatory filings. In this podcast, we will discuss how Catalent is working to simplify the supply chain, develop processes scalable for late-stage and commercial needs, and accelerate timelines for production of clinical materials

Thursday, January 27th 2022 at 11AM EST | 4PM GMT | 8AM PST In this webinar, experts provide an overview of the needs of different patient populations, and examine the common challenges leading to non-compliance. The experts also discuss how an orally dissolving tablet (ODT) provides a solution to address patient challenges and enables potentially more successful treatments.

With more than 30 years’ experience, Catalent offers end-to-end solutions for multiple inhalation dose forms.

Catalent is a global leader in clinical supply services with flexible solutions for small molecules, biologics, and cell and gene therapies, including integrated services to accelerate products to the clinic.

Catalent’s OneXpress™ solution combines phase-appropriate scale and technologies with expertise across diverse dose forms to simplify development and accelerate a programme towards commercialisation.

*Wednesday, May 5, 2021 at 10am EDT | 7am PDT | 3pm BST | 4pm CEST* What size API would work for an ODT targeting sublingual or enteric delivery? Why would one consider an ODT over a tablet or capsule for standard G.I. absorption? Learn more as Catalent discusses ODT technologies in this upcoming webinar. *On Demand Until May 5, 2022*

Catalent is the global leader in drug development and delivery, offering innovative development and manufacturing solutions for oral dosage forms.

**Tuesday, March 23, 2021, 1pm EDT | 10am PDT | 6pm GMT | 7pm CET*** Biopharmaceutical products in development continue to increase in complexity, which poses a challenge for pharmaceutical companies that are looking to improve speed and efficiency of biologic development. Join us for this webinar where we will discuss new cell line development methodologies, as well as new instrumentation, that are enabling these complex programs to be performed with shortened development timelines. *** On demand available after final airing until March 23, 2022.***

OptiForm® Total Supply integrates drug development, manufacturing, and clinical supply to streamline and accelerate projects

CTSuccess™ by Catalent employs proactive clinical supply risk evaluation and tailored strategies to ensure on-time start up and efficient material supply throughout clinical studies.

***Live: Tuesday, January 19, 2021, at 11am EST | 8am PST | 4pm GMT | 5pm CET ***Join this webcast to learn best practices to ensure a smooth transition from Phase 1 to Phase 2 studies, how a clinical supply provider can enable this process, as well as the role that integrated solutions can play***On demand available after final airing until Jan. 19, 2022***

*** Live: Wednesday, November 11, 2020 | 8:30 AM EDT – 4:00 PM EDT *** 2020 Bio/Pharma Virtual Congress: Join Pharmaceutical Technology® and BioPharm International® for this online event that will explore the latest developments in formulation, manufacturing, and innovative drug dosage forms, as well as detailed discussions about crucial topics impacting the industry. ***On demand available after final airing until 11/11/2021

**Thursday, October 29, 2020 at 11am EDT| 8am PDT| 3pm GMT| 4pm CET***An increasing number of new chemical entities (NCEs) present with bioavailability issues. Low bioavailability is associated with increased pharmacokinetic variability in both preclinical species and humans, which can lead to additional development challenges. An expert will discuss API-sparing development techniques and innovative scalable drug delivery technologies that are proven to improve solubility and enhance bioavailability using a minimal amount of API. ***On demand available after final airing until Oct. 29, 2021***

*** Live: Monday, Oct. 26, 2020, 11am EDT| 8am PDT| 3pm GMT| 4pm CET *** What are typical challenges sponsors encounter during Phase 3 clinical trials? How can advance preparation during Phase 2 help mitigate risks? Learn effective strategies to avoid surprises and problems in late-stage trials from experience clinical trial and supply experts. ***On demand available after final airing until Oct. 26, 2021***

Review how data-driven approaches, including physiologically based pharmacokinetic (PBPK) modeling, parallel formulation screening, API sparing techniques, and optimal early dosing strategies can help avoid development pitfalls for small-molecule drug candidates on the path to clinic. Live: Wednesday, Sept. 23, 2020 at 11am EDT| 8am PDT| 4pm BST| 5pm CEST On demand available after final airing until Sept. 23, 2021